Abstract
Hepatitis C is practically globally prevalent disease with almost 200 million infected, of whom the vast majority suffer from the disease in its chronic form. Long-term persistence of infection in the organism leads to the development of many pathological conditions, it is especially cirrhosis with all its complications, including hepatocellular carcinoma (HCC).
Chronic hepatitis C (chronic HCV) is responsible for the formation of more than half the cases of HCC in Europe, the United States and Japan. Disease transmission routes are different between developing and economically developed countries.
In the field of treatment of chronic hepatitis C occurred in the last five years, a significant shift towards more efficient, but also significantly more expensive drugs. Still lacks an effective, globally applicable vaccine against the disease, which would certainly meant a significant shift in the fight against this disease.